TOKYO/NEW YORK -- The U.S. Food and Drug Administration on Thursday officially approved lecanemab, an Alzheimer's disease treatment developed by Japanese drugmaker Eisai and American partner Biogen.
Pharmaceuticals
Eisai-Biogen Alzheimer's drug receives full U.S. approval
Treatment expected to spread rapidly with public medical insurance coverage
Lecanemab is administered to a patient during a clinical trial in the U.S. (Photo courtesy of Eisai)
Read Next
%2520%E3%81%AE%E3%82%B3%E3%83%94%E3%83%BC.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
